Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?

Current Osteoporosis Reports

Volumn 5, Issue 1, 2007, Pages 3-7

  Gold, Deborah T ^a   Silverman, Stuart L ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BACK PAIN; ESTROGENS; FATIGUE; FEMALE; FRACTURES, SPONTANEOUS; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES; TAMOXIFEN; UNITED STATES;

EID: 33947418863     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/BF02938616     Document Type: Review

References (46)

1. •• US Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004. Available at www.surgeongeneral.gov/library/bonehealth/ This thorough report on osteoporosis and bone health in America was developed through contributions of many leaders in the bone field. It discusses the diagnosis, treatment, management, and prevention of osteoporosis.
2. Kronenberg F: Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
3. South-Paul JE: Osteoporosis: part I. Evaluation and assessment. Am Fam Physician 2001, 63:897-904, 908.
4. Tosteson AN, Hammond CS: Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002, 20:289-303.
5. Cook DJ, Guyatt GH, Adachi JD, et al.: Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 1993, 36:750-756.
6. Silverman SL, Minshall ME, Shen W, et al.: Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001, 44:2611-2619.
7. Silverman SL, Piziak VK, Chen P, et al.: Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheum 2005, 32:2405-2409.
8. Gold DT, Silverman SL: The Downward Spiral of Vertebral Osteoporosis: Consequences. Los Angeles, CA: Cedars-Sinai Medical Center; 2003.
9. • Kado DM, Huang MH, Barrett-Connor E, Greendale GA: Hyperkyphotic posture and poor physical functional ability in older community-dwelling men and women: the Rancho Bernardo study. J Gerontol A Biol Sci Med Sci 2005, 60:633-637. Using the Rancho Bernardo cohort of 1578 older men and women who were hyperkyphotic, this group found that people with hyperkyphosis were more likely to have problems with physical function than those without.
10. Lips P, van Schoor NM: Quality of life in patients with osteoporosis. Osteoporos Int 2005, 16:447-455.
11. Cockerill W, Lunt M, Silman AJ, et al.: Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004, 15:113-119.
12. Adachi JD, Loannidis G, Berger C, et al.: The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001, 12:903-908.
13. Lombardi I Jr, Oliveira LM, Monteiro CR, et al.: Evaluation of physical capacity and quality of life in osteoporotic women. Osteoporos Int 2005, 15:80-85.
14. Gold DT: The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001, 27:255-262.
15. Joel ME, Le Gales C: Social and economic aspects of osteoporosis. Curr Opin Rheumatol 1998, 10:362-367.
16. Lindsay R, Burge RT, Strauss DM: One year outcomes and costs following a vertebral fracture. Osteoporos Int 2005, 16:78-85.
17. Segal E, Zinnman C, Raz B, et al.: Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment. Age Ageing 2005, 34:507-510.
18. Johnell O: Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality. J Intern Med 1996, 239:299-304.
19. Roberto KA: Care practices and quality of life of rural older women with osteoporosis. J Am Med Womens Assoc 2004, 59:295-301.
20. Gold DT: Osteoporosis and quality of life psychosocial outcomes and interventions for individual patients [review]. Clin Geriatr Med 2003, 19:271-280.
21. Mulherin DM, Smith JA, Price T: Is patient anxiety about osteoporosis sufficient indication for measuring bone mineral density? [letter]. Clin Exp Rheumatol 2000, 18:789.
22. Campbell MK, Torgerson DJ, Thomas RE, et al.: Direct disclosure of bone density results to patients: effect on knowledge of osteoporosis risk and anxiety level. Osteoporos Int 1998, 8:584-590.
23. Purser JL, Pieper CF, Branch LG, et al.: Spinal deformity and mobility self-confidence among women with osteoporosis and vertebral fractures. Aging Clin Exp Res 1999, 11:235-245.
24. Gold DT, Shipp KM, Lyles KW: Managing patients with complications of osteoporosis. Endocrinol Metab Clin North Am 1998, 27:485-496.
25. Gold DT, Silverman SL: Osteoporosis self-management: Choices For Better Bone Health. South Med J 2004, 197:551-554.
26. Kahl KG, Greggersen W, Rudolf S, et al.: Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 2006, 68:669-674.
27. Cizza G, Ravn P, Chrousos GP, Gold PW: Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 2001, 12:198-203.
28. Coelho R, Silva C, Maia A, et al.: Bone mineral density and depression: a community study in women. J Psychosom Res 1999, 46:29-35.
29. Michelson D, Stratakis C, Hill L, et al.: Bone mineral density in women with depression. N Engl J Med 1996, 335:1176-1181.
30. Johnell O, Kanis J: Epidemiology of osteoporotic fractures. Osteoporos Int 2005, 16(suppl 2):S3-S7.
31. • Brenneman SK, Barrett-Connor E, Sajjan S, et al.: Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006, 21:809-816. Using data from the NORA study, these investigators examined the impact of nonspine and nonhip fractures on quality of life in older and younger women. They found that fracture recency had a substantial effect on the impact of the fracture on health-related quality of life.
32. Hlatky MA, Boothroyd D, Vittinghoff E, et al.: Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002, 287:591-597.
33. Hays J, Ockene JK, Brunner RL, et al.: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003, 348:1839-1854.
34. Smith AJ, Hall DR, Grove D: Postmenopausal hormone therapy and quality of life. Int J Gynaecol Obstet 2006, 95:267-271.
35. North American Menopause Society: Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003, 10:113-132.
36. Stefanick ML: Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005, 118(suppl 12B):64-73.
37. Pinkerton JV, Zion AS: Vasomotor symptoms in menopause: where we've been and where we're going. J Women's Health 2006, 15:135-145.
38. Seeman E, Crans GG, Diez-Perez A, et al.: Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006, 17:313-316.
39. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645.
40. Barrett-Connor E, Cauley JA, Kulkarni PM, et al.: Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004, 19:1270-1275.
41. Day R, Ganz PA, Costantino JP, et al.: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999, 17:2659-2669.
42. Land SR, Wickerham DL, Costantino JP, et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2742-2751.
43. Utian WH, Janata JW, Barbier S, et al.: Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) Scale. Menopause 2004, 11:275-280.
44. Silverman SL: Selecting patients for osteoporosis therapy. Curr Osteoporos Rep 2006, 4:91-95.
45. Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
46. Lippman ME, Cummings SR, Disch DP et al.: Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006, 12:5242-5247.